lonsys marketing authorisation suspended following discovery of self-activating units

摘要

Janssen-Cilag s lonsys (fentanyl iontophoretic transdermal system) marketing authorisation has been suspended across Europe. This follows a recall in September, after the European Medicines Agency concluded that the products benefits for post-operative pain no longer outweigh its risks, because some units were found to self-activate, which could cause overdose.